izokibep

Acelyrin Plans IPO to Fund Pivotal Tests of Drug That Could Rival AbbVie’s Humira

Biotech IPOs continues to be almost non-existent, but Acelyrin wants to see if the public markets have an appetite for its lead drug candidate. The small protein drug could match up favorably against blockbuster biologics and it has reached pivotal testing in three inflammatory disorders.

By Frank Vinluan

Pharma BioPharma,

Acelyrin raises $250M, licenses antibody drug that could rival Novartis, Lilly meds

Acelyrin has in-licensed izokibep, an antibody drug developed by Affibody that could offer advantages compared to currently available monoclonal antibodies. The drug addresses the same target as blockbuster immunology drugs marketed by Novartis and Eli Lilly.

By Frank Vinluan